Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
PURITAN MEDICAL

Digital Imaging System Offers Superior Multiple-Biomarker Tissue Analysis

By BiotechDaily International staff writers
Posted on 09 Apr 2012
Image: Tissue IA 2.0 – Automated Image Analysis for Brightfield and Fluorescence Digital Pathology (Photo courtesy of Leica Microsystems).
Image: Tissue IA 2.0 – Automated Image Analysis for Brightfield and Fluorescence Digital Pathology (Photo courtesy of Leica Microsystems).
The Tissue IA 2.0 image analysis system provides pathology researchers with superior capability for immunohistochemistry (IHC) biomarker quantification and tissue localization. The system provides a unique combination of flexibility, automation, and ease-of-use that make it an excellent tool for discovery and translational research in pathology.

Developed and released by Leica Microsystems (Leica; Wetzlar, Germany), the research-only system, Tissue IA 2.0 features fluorescence and brightfield analysis capabilities in a single platform as well as precision cell modeling. Advanced dual staining capabilities enable researchers to identify cell cohorts at the molecular level. Use one marker to identify a population of interest and then quantify expression using a second, providing greater understanding of sample slides. Algorithms are easily adjusted and optimized for different markers, tissue, and protocols, giving a flexible platform, also for drug discovery applications.

Tissue IA 2.0 provides expert tools for retrieval of quantitative, reproducible data from tissue-based IHC studies. Powerful color separation and multimarker co-localization functionality provides advanced insight and unbiased measurement of multiple antigen immunostaining in brightfield or fluorescent samples. Sophisticated cell modeling accurately detects and quantifies differential expression of staining in cellular compartments, providing detailed insight into cytoplasmic, membrane, and nuclear biomarker localization.

“Mulitplexing is of growing importance in translational research and tools to help quantify the expression and location of multiple biomarkers concurrently in tissue are a real requirement. TissueIA 2.0 delivers for the user through offering chromogenic and fluorescence quantification and co-localization, cell based histoscoring on multicompartmental IHC staining and the power to include and exclude cell populations based on biomarker expression. In conjunction with our SCN400 F and Ariol platforms, this further expands our Digital Pathology portfolio for the life science and clinical researcher and demonstrates our ongoing commitment to this area,” said Dr. Donal O’Shea, Head of Digital Pathology in Leica Microsystems. With Tissue IA 2.0, Leica's Digital Pathology portfolio provides streamlined end-to-end excellence in capture, management, and analysis of digital pathology images.

With high throughput batch analysis capacity, Tissue IA 2.0 will process whole slides, regions of interest or tissue microarray cores, and automatically integrate analysis results with user’s slides. A built-in upload interface facilitating integration of algorithms from third party software solutions, gives greater flexibility to further expand analysis options. The system includes a web-accessible interface, enabling users to take their analyses wherever they go.

Leica Microsystems will be at the American Association for Cancer Research Annual Meeting 2012, March 31 to April 4, Chicago, IL. Visit booth 4103 to experience this new image analysis solution for Digital Pathology.


Related Links:
Leica Microsystems
Tissue IA 2.0



Channels

Genomics/Proteomics

view channel
Image: Researchers have generated disease-free stem cells from patients with mitochondrial disease that can be converted into any cell type including neuronal progenitors (left) or heart cells (right). These could potentially be used for future transplantation into patients (Photo courtesy of Salk Institute of Biological Studies).

Methods Developed to Generate Normal Stem Cells from Patients with Mitochondrial Defects

A recent paper described two methods for converting cells from patients with mitochondrial defects into normal pluripotent stem cells that could be induced to differentiate into several different types of tissues.... Read more

Drug Discovery

view channel
Image: A new micelle delivery system for the protective polyphenols resveratrol and quercetin (mRQ) may have value in cancer chemotherapy (Photo courtesy of Oregon State University).

Micelles Containing Resveratrol and Quercetin Reverse Doxorubicin Cardiotoxicity

Cancer researchers blocked the toxic effects of the cancer drug doxorubicin (DOX) by administering it together with the plant antioxidants resveratrol and quercetin. Although in use for more than 40... Read more

Business

view channel

Teva Buys Allergan Generic Business Unit

Teva Pharmaceutical Industries (Petah Tikva, Israel) has bought the Allergan (Irvine, CA, USA) generic drugs business for USD 40.5 billion in cash and stock, solidifying its position as the world's largest generic drug maker. Under the terms of the agreement, Teva will pay USD 33.75 billion in cash and USD 6.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.